Cargando…

The challenge of emerging SARS-CoV-2 mutants to vaccine development

Detalles Bibliográficos
Autores principales:	Li, Rong, Liu, Jun, Zhang, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, and Genetics Society of China. Published by Elsevier Limited and Science Press. 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056881/ https://www.ncbi.nlm.nih.gov/pubmed/33994322 http://dx.doi.org/10.1016/j.jgg.2021.03.001

Ejemplares similares

Timely development of vaccines against SARS-CoV-2
por: Lu, Shan
Publicado: (2020)

Emerging SARS-CoV-2 Variants and Subvariants: Challenges and Opportunities in the Context of COVID-19 Pandemic
por: Rahman, Smaranika, et al.
Publicado: (2022)

SARS-CoV-2 vaccination for immune-comprised patients: More is required
por: Li, Hui, et al.
Publicado: (2021)

Inactivated SARS-CoV-2 vaccine for people with HIV
por: Wolday, Dawit, et al.
Publicado: (2022)

Is there a post-SARS-CoV-2 vaccination dementia?
por: Fiorini, Ana C., et al.
Publicado: (2022)

The challenge of asymptomatic SARS-CoV-2 transmission in care homes
por: Belmin, Joël, et al.
Publicado: (2021)

Disease Prevalence Matters: Challenge for SARS-CoV-2 Testing
por: Lau, Chin-Shern, et al.
Publicado: (2021)

Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development
por: Cohen, Samuel A., et al.
Publicado: (2020)

The potential of developing a protective peptide‐based vaccines against SARS‐CoV‐2
por: Shalash, Ahmed O., et al.
Publicado: (2022)

The way of SARS-CoV-2 vaccine development: success and challenges
por: Dong, Yetian, et al.
Publicado: (2021)

A new group at increased risk of a SARS-CoV-2 infection emerges: The recently vaccinated
por: Hoehl, Sebastian, et al.
Publicado: (2021)

Unanticipated efficacy of SARS-CoV-2 vaccination in older adults
por: Pawelec, Graham, et al.
Publicado: (2021)

Multicomponent vaccines to fight SARS-CoV-2 variants of concern
por: Cassone, Antonio, et al.
Publicado: (2021)

SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination?
por: Antonopoulou, Tania, et al.
Publicado: (2022)

Questioning the justification for a fourth SARS-CoV-2 vaccine
por: Calderon-Margalit, Ronit, et al.
Publicado: (2022)

Rapid and robust bioanalytical assays are critical for SARS-CoV-2 therapeutic and vaccine development and beyond
por: Kar, Sumit, et al.
Publicado: (2020)

The pathogenesis and alternative treatment of SARS-CoV2
por: Choi, Jun-Yong, et al.
Publicado: (2020)

SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines
por: Salvatori, Giovanni, et al.
Publicado: (2020)

Pregnant people deserve the protection offered by SARS-CoV-2 vaccines
por: Maykin, Melanie M., et al.
Publicado: (2021)

Positive aspects of the mRNA platform for SARS-CoV-2 vaccines
por: Hajissa, Khalid, et al.
Publicado: (2021)

COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants
por: Cevik, Muge, et al.
Publicado: (2021)

Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants
por: Su, Shan, et al.
Publicado: (2021)

Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks
por: Billington, John, et al.
Publicado: (2020)

Approaches and Challenges in SARS-CoV-2 Vaccine Development
por: Dagotto, Gabriel, et al.
Publicado: (2020)

Development of SARS-CoV-2 Vaccine: Challenges and Prospects
por: Mahboob, Tooba, et al.
Publicado: (2023)

A Commentary on “Omicron SARS-CoV-2 variant: Reasons of emergence and lessons learnt” (Int J Surg 2022;97:106198) Contact-tracing and global vaccine equity: Crucial responses to emergence of the Omicron SARS-CoV-2 variant
por: Rahimi, Farid, et al.
Publicado: (2022)

Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests
por: Eyal, Nir, et al.
Publicado: (2021)

Invasive pulmonary aspergillosis complicating SARS-CoV-2 pneumonia: A diagnostic challenge
por: Antinori, Spinello, et al.
Publicado: (2020)

Skin rashes after SARS‐CoV‐2 vaccine: which relationship, if any?
por: Patruno, Cataldo, et al.
Publicado: (2021)

Vaccine against SARS-CoV-2 in previously infected health care workers
por: Parisi, Saverio Giuseppe
Publicado: (2021)

Increasing SARS-CoV-2 vaccination rates among Black people in Canada
por: Eissa, Azza, et al.
Publicado: (2021)

Pathogenicity of SARS‐CoV‐2 Omicron
por: Chu, Hin, et al.
Publicado: (2022)

Antigenic imprinting in SARS‐CoV‐2
por: Reincke, S. Momsen, et al.
Publicado: (2022)

SARS-CoV-2 vaccination in the context of original antigenic sin
por: Petráš, Marek, et al.
Publicado: (2021)

Immunodominant epitopes based serological assay for detecting SARS-CoV-2 exposure: Promises and challenges
por: Quadeer, Ahmed Abdul
Publicado: (2020)

Diagnosing SARS-CoV-2 associated Guillain-Barre syndrome in children is challenging like in adults
por: Finsterer, Josef
Publicado: (2022)

The potential risks of delaying the second vaccine dose during the SARS-CoV-2 pandemic
por: Humphreys, I R, et al.
Publicado: (2021)

Why we may need to rethink future SARS-CoV-2 vaccination strategies
por: Klimek, Peter
Publicado: (2021)

Validation of the effectiveness of SARS-CoV-2 vaccines in older adults in “real-world” settings
por: Weng, Nan-ping, et al.
Publicado: (2021)

The role of observational studies based on secondary data in studying SARS-CoV-2 vaccines
por: Barda, Noam, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f22590g2c9c9euulm7q77k2bu5